CPG
TCRT icon

Cornerstone Planning Group’s Alaunos Therapeutics TCRT Stock Holding History

Cornerstone Planning Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$379 Buy
+3
New +$435 ﹤0.01% 1475

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Addison Capital Conshohocken, Pennsylvania $562M AUM 18.57% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Cornerstone Planning Group's TCRT Position: Q4 2022 in Review

Cornerstone Planning Group opened a new position in Alaunos Therapeutics (TCRT) in Q4 2022: 3 shares worth $379. The stake represents ﹤0.01% of the portfolio and ranks #1475 among its holdings.

122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

  • Cornerstone Planning Group held 3 shares of Alaunos Therapeutics worth $379 as of Q4 2022.
  • Alaunos Therapeutics was a new Cornerstone Planning Group position in Q4 2022.
  • Alaunos Therapeutics made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q4 2022, its #1475 holding.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on Cornerstone Planning Group's 13F filing for Q4 2022, filed 14 Feb 2023.